An ex vivo human bone marrow milieu identifies CDH2 as a driver of niche-mediated treatment resistance in leukaemia
D. Pal, H. Blair, S. Boyd, S. Angel, S. Nizami, A. Isa, M. Beckett, R. Nelson, A. Wilson, M. Singh, S. Sankar, R. Tirtakusuma, S. Nakjang, C. Knill, A. Fuller, , J. Vormoor
This study identifies CDH2 as a driver of niche-mediated treatment resistance in leukemia and shows that ADH-1 can effectively target this resistance in preclinical models.
bioRxiv · Jun 18, 2021Cancer Biology